



Please type a plus sign (+) inside this box ☐

09-19-05

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/017,081
Filing Date	October 24, 2001
First Named Inventor	Avi J. Ashkenazi
Group/Art Unit	1647
Examiner Name	Robert S. Landsman
Attorney Docket Number	39780-2630 P1C69

Total Number of Pages in This Submission

110

ENCLOSURES (check all that apply)

☒ **Fee Transmittal Form**

☐ Fee Attached

☒ **Response/Amendment**

☐ After Final

☐ Version With Markings Showing
Changes

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☒ **Information Disclosure Statement
with 14 References**

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete
Application

☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53

☐ Copy of Notice

☐ Copy of an Assignment

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition Routing Slip (PTO/SB/69)
and Accompanying Petition

☐ Petition to Convert to a
Provisional Application

☐ Power of Attorney, by Assignee to
Exclusion of Inventor Under 37 C.F.R.
§3.71 With Revocation of Prior Powers

☐ Terminal Disclaimer

☐ Small Entity Statement

☐ Request for Refund

☐ After Allowance Communication to
Group

☐ Appeal Communication to Board of
Appeals and Interferences

☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ **ADDITIONAL ENCLOSURE(S)
(PLEASE IDENTIFY BELOW):**

☒ **Return Postcard**

Remarks

**AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN
CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39780-
2630P1C69.**

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	HELLER EHRMAN LLP	BARRIE D. GREENE (Reg. No. 46,740)
	275 Middlefield Road, Menlo Park, California 94025	Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature	<i>Barrie D. Greene</i>	
Date	SEPTEMBER 16, 2005	Customer Number: 35489

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: **MAIL STOP AMENDMENT**, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: **SEPTEMBER 16, 2005**

Express Mail Label **EL 976 548 777 US**

Typed or printed name	L. ACOSTA		
Signature	<i>L. Acosta</i>	Date	SEPTEMBER 16, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ___, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

09/20/2005 10:00:00 00000031 084631 10017001

01 FEB 2006



12

PTO/SB/17 (12-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2005

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/017,081
Filing Date	October 24, 2001
First Named Inventor	Avi J. Ashkenazi
Examiner Name	Robert S. Landsman
Art Unit	1647
Attorney Docket No.	39780-2630 P1C69

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number
Deposit
Account
Name

08-1641 (39780-2630P1C69)

HELLER EHRMAN, LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	300	2001	150	Utility filing fee	
1002	200	2002	100	Design filing fee	
1003	200	2003	100	Plant filing fee	
1004	300	2004	150	Reissue filing fee	
1005	200	2005	100	Provisional filing fee	
SUBTOTAL (1)					(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	<input type="text"/>	= <input type="text"/>
Independent Claims	<input type="text"/>	- 3** =	<input type="text"/>	X	<input type="text"/>	= <input type="text"/>
Multiple Dependent					<input type="text"/>	= <input type="text"/>

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	50	2202	25	Claims in excess of 20	
1201	200	2201	100	Independent claims in excess of 3	
1203	360	2203	180	Multiple dependent claim, if not paid	
1204	200	2204	100	** Reissue independent claims over original patent	
1205	50	2205	25	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	
1403	1,000	2403	500	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1,500	2453	750	Petition to revive - unintentional	
1501	1,400	2501	700	Utility issue fee (or reissue)	
1502	800	2502	400	Design issue fee	
1503	1,100	2503	550	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

SUBMITTED BY

(Complete (if applicable))

Name (Print/Type)	Barrie D. Greene	Registration No. (Attorney/Agent)	46,740	Telephone	(650) 324-7000
Signature		Date	September 16, 2005		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



09-19-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Landsman, Robert S.
)	
Avi J. ASHKENAZI, et al.)	Art Unit: 1647
)	
Application Serial No. 10/017,081)	Confirmation No: 4135
)	
Filed: October 24, 2001)	Attorney's Docket No. 39780-2630P1C69
)	
For: SECRETED AND TRANSMEMBRANE)	Customer No. 35489
POLYPEPTIDES AND NUCLEIC)	
ACIDS ENCODING THE SAME)	

EXPRESS MAIL LABEL NO. EL 976 548 777 US
DATE MAILED: SEPTEMBER 16, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form Supplemental PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.


09/21/2005 JBALINAN 00000031 10017081

01 FC:1806 180.00 DA


- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☒ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2630 P1C69).**

Respectfully submitted,

Dated: September 16, 2005


Barrie D. Greene (Reg. No.46,740)

HELLER EHRMAN, LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

 Form PTO-1449 INFORMATION DISCLOSURE STATEMENT		Attorney's Docket No. 39780-2630 P1C69	Application Serial No. 10/017,081					
		Applicant(s) Avi J. ASHKENAZI et al.						
(use several sheets if necessary)		Filing Date: October 24, 2001	Group Art Unit: 1647					
U.S. PATENT DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)								
Examiner Initials	Ref. No.	Title						
	1.	Dayhoff, Accession No.: P_AAB65300, WO 200073454-A1, Pub Date: December 7, 2000, A. J. Ashkenazi et al.						
	2.	Dayhoff, Accession No.: P_AAB19580, WO 200053760-A2, Pub Date: September 14, 2000, N. Ferrara et al.						
	3.	Dayhoff, Accession No.: P_AAB44273, WO 200053756-A2, Pub Date: September 14, 2000, A. J. Ashkenazi et al.						
	4.	Dayhoff, Accession No.: P_AAY41717, WO 9946281-A2, Pub Date: September 16, 1999, W. I. Wood et al.						
	5.	Dayhoff, Accession No.: P_AAB27653, WO 200053757-A2, September 14, 2000, A. J. Ashkenazi et al.						
	6.	GenBank, Accession No.: P_AAF44269, WO 200073454-A1, Pub Date: December 7, 2000, A. J. Ashkenazi et al.						
	7.	GenBank, Accession No.: P_AAA88517, WO 200053760-A2, Pub Date: September 14, 2000, N. Ferrara et al.						
	8.	Benjamin et al., "Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal", Proc. Natl. Sci. USA, Vol. 94, pp 8761-8766, August 1997.						
	9.	Bozyczko-Coyne et al., "A rapid fluorometric assay to measure neuronal survival in vitro", Journal of Neuroscience Methods, Vol. 50, pp 205-216, 1993.						
	10.	Fontaine et al., "Survival of Purified Rat Photoreceptors In Vitro Is Stimulated Directly by Fibroblast Growth Factor-2", The Journal of Neuroscience, Vol. 18, No. 23, pp 9662-9672, December 1, 1998.						
	11.	Jiang et al., "Selenium-Induced Inhibition of Angiogenesis in Mammary Cancer at Chemopreventive Levels of Intake", Molecular Carcinogenesis, Vol. 26, pp 213-225, 1999.						
	12.	Levin et al., "Effect of Lipid Peroxidation Inhibition on Retinal Ganglion Cell Death", Investigative Ophthalmology & Visual Science, Vol. 37, No. 13, December 1996.						
	13.	Otori et al., "Neurotoxic Effects of Low Doses of Glutamate on Purified Rat Retinal Ganglion Cells", Investigative Ophthalmology & Visual Science, Vol. 39, No. 6, May 1998.						
	14.	Otori et al., "Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells", Brain Research, Vol. 961, pp 213-219, 2003.						

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	